程序性死亡受体-1抑制药免疫相关不良反应的文献计量学分析

Programmed Death-1 Inhibitors’Immune-related Adverse Reactions Bibliometrological Analysis

目的:对程序性死亡受体-1(PD-1)抑制药免疫相关不良反应的文献发表状况进行统计分析。方法:在中国知网(CNKI)《中国学术期刊(网络版)》和科学引文索引数据库(Web of Science)检索内容为PD-1抑制药免疫相关不良反应的已发表文献,检索截止日期均为2019年10月11日,用Excel、VOSviewer等软件对检索结果进行包括年发文量、作者、机构、引用率等项目的文献计量分析。结果:经排除标准筛选后,在中国知网共检索到64篇文献,2019年发文量最高,宁波市医疗中心李惠利医院是发文量最多的机构,Web of Science中检索到881篇相关文献,2019年发文量最多,美国共发表436篇文献,是所有国家地区中发文最多的,发表文献最多的研究机构是斯隆凯特琳癌症中心。结论:PD-1抑制药免疫相关不良反应内容的文献近年来发文量逐年升高,但我国发文数量和质量总体来说仍旧偏低,未来还需加强对这方面的研究。

Objective:To study the publishing situation of literatures on immune-related adverse reactions of programmed death-1(PD-1)inhibitors.Methods:Assays about PD-1 inhibitors’adverse reactions were searched in China Academic Journal Network Publishing Database(CNKI)and Science Citation Index Database(SCI)until October 11 th,2019.Bibliometric analysis was done by Excel,VOSviewer,etc.including the annual amount of publications,authors,institutions,citation rate,etc.Results:After screening by exclusion criteria,a total of 64 articles were retrieved from CNKI.2019 was the year with the most assay published,and Li Huili Hospital of Ningbo Medical Center was the institution.881 related articles were retrieved from Web of Science.2019 was the year with the most assay published.The United States had published 436 related articles,which published the most related assays in all countries.The institution which posted the most articles was Sloan Kettering Cancer Center.Conclusion:The number of articles on PD-1 inhibitors’immune-related adverse reactions has been increasing in recent years.But the number and the quality of papers in China are still far from enough.Research on this topic needs to be further matured.